<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article article-type="research-article" dtd-version="2.3" xml:lang="EN" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">743708</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2022.743708</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Paeoniflorin Inhibits ASK1-TF Axis by Up-Regulating SOCS3 to Alleviate Radiation Enteritis</article-title>
<alt-title alt-title-type="left-running-head">Sheng et&#x20;al.</alt-title>
<alt-title alt-title-type="right-running-head">Paeoniflorin Alleviates Radiation Enteritis</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Sheng</surname>
<given-names>Lei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hu</surname>
<given-names>Fan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yu</surname>
<given-names>Hanqing</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tao</surname>
<given-names>Xueyou</given-names>
</name>
<xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
<xref ref-type="fn" rid="fn1">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1583196/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>Rumeng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gu</surname>
<given-names>Yufeng</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Lu</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kong</surname>
<given-names>Hong</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miao</surname>
<given-names>Chen</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Fei</surname>
<given-names>Wenjing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1261522/overview"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Yang</given-names>
</name>
<xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jia</surname>
<given-names>Jinhui</given-names>
</name>
<xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Xia</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>He</surname>
<given-names>Xueming</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hu</surname>
<given-names>Liang</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1340704/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Ma</surname>
<given-names>Jianxin</given-names>
</name>
<xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Wen-Tao</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/992094/overview"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Yang</surname>
<given-names>Mi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="aff8">
<sup>8</sup>
</xref>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology, Nanjing Medical University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of clinical laboratory, Children&#x2019;s Hospital of Nanjing Medical University</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff4">
<sup>4</sup>
<institution>Department of Anesthesiology, Yangzhou Maternal and Child Health Hospital Affiliated with Yangzhou Medical University</institution>, <addr-line>Yangzhou</addr-line>, <country>China</country>
</aff>
<aff id="aff5">
<sup>5</sup>
<institution>The Affiliated Cancer Hospital of Nanjing Medical University and Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff6">
<sup>6</sup>
<institution>Department of Orthopedics, Jiangsu Province Hospital of Integration of Chinese and Western Medicine</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<aff id="aff7">
<sup>7</sup>
<institution>Center for Clinical Research and Translational Medicine, The Affiliated Lianyungang Oriental Hospital of Kangda College of Nanjing Medical University</institution>, <addr-line>Lianyungang</addr-line>, <country>China</country>
</aff>
<aff id="aff8">
<sup>8</sup>
<institution>The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School</institution>, <addr-line>Nanjing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/716258/overview">Patricia Lalor</ext-link>, University of Birmingham, United&#x20;Kingdom</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/333573/overview">Dapeng Chen</ext-link>, Dalian Medical University, China</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1542372/overview">Takuya Noguchi</ext-link>, Tohoku University, Japan</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Mi Yang, <email>yangmi@nju.edu.cn</email>; Liang Hu, <email>lianghu@njmu.edu.cn</email>; Jianxin Ma, <email>mjx3416@163.com</email>; Wen-Tao Liu, <email>painresearch@njmu.edu.cn</email>
</corresp>
<fn fn-type="other">
<p>This article was submitted to Gastrointestinal and Hepatic Pharmacology, a section of the journal Frontiers in Pharmacology</p>
</fn>
<fn fn-type="equal" id="fn1">
<label>
<sup>&#x2020;</sup>
</label>
<p>These authors have contributed equally to this&#x20;work</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>14</day>
<month>03</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="collection">
<year>2022</year>
</pub-date>
<volume>13</volume>
<elocation-id>743708</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>31</day>
<month>01</month>
<year>2022</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2022 Sheng, Hu, Yu, Tao, Jia, Gu, Chen, Kong, Miao, Fei, Yang, Jia, Zhu, He, Hu, Ma, Liu and Yang.</copyright-statement>
<copyright-year>2022</copyright-year>
<copyright-holder>Sheng, Hu, Yu, Tao, Jia, Gu, Chen, Kong, Miao, Fei, Yang, Jia, Zhu, He, Hu, Ma, Liu and Yang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these&#x20;terms.</p>
</license>
</permissions>
<abstract>
<p>Radiation enteritis is one of the main adverse effects of radiotherapy, presenting with a poorly understood etiology and limited options for therapy. Intestinal inflammation and ischemia are the core mechanisms of radiation enteritis. Suppressor of cytokine signaling 3 (SOCS3) is an endogenous &#x201c;inflammation brake.&#x201d; We hypothesized that paeoniflorin, a pinane monoterpene bitter glycoside, could increase SOCS3 expression to reduce inflammation and ischemia and improve enteritis in mice. Laser Doppler flowmetry was used to detect changes in intestinal blood flow. RAW264.7 and human umbilical vein endothelial cells were used to investigate the mechanism of action of paeoniflorin. It was observed that radiation caused high mortality, intestinal inflammatory responses, and low blood flow in mice. Paeoniflorin effectively alleviated intestinal atrophy, prevented thrombosis, improved radiation enteritis, and reduced mortality in mice undergoing radiotherapy. In addition, paeoniflorin increased the release of growth arrest-specific gene 6 (Gas6) and phosphorylation of the Axl receptor, subsequently inducing the expression of SOCS3 and inhibiting the expression of p-apoptosis signal-regulating kinase 1 and tissue factor <italic>in vivo</italic> and <italic>in&#x20;vitro</italic>. Based on our findings, we suggest that paeoniflorin is potentially effective in alleviating radiation enteritis <italic>via</italic> the activation of the Gas6/Axl/SOCS3 axis and subsequent reduction in intestinal inflammation and ischemia.</p>
</abstract>
<kwd-group>
<kwd>radiation enteritis</kwd>
<kwd>paeoniflorin</kwd>
<kwd>SOCS3</kwd>
<kwd>ASK1</kwd>
<kwd>TF</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="s1">
<title>Introduction</title>
<p>Radiation enteritis (RE) is a gastrointestinal complication caused by radiotherapy that affects up to 13% of patients (<xref ref-type="bibr" rid="B17">Modlin et&#x20;al., 2005</xref>). The primary clinical manifestations are nausea, vomiting, abdominal pain, diarrhea, and tenesmus. Currently, most clinical treatment methods are limited to the alleviation of symptoms, such as diarrhea and bloody stools, caused by enteritis, including antibacterial and anti-infective drugs. Unfortunately, the efficacy of these treatments is far from satisfactory owing to the condition&#x2019;s complex molecular mechanisms.</p>
<p>Intestinal inflammation is involved in the development of chemotherapy-induced enteritis. Extensive research has focused on the production of inflammatory cytokines (<xref ref-type="bibr" rid="B8">G&#xe9;rard et&#x20;al., 2006</xref>), destruction of intestinal immune and chemical barriers, intestinal flora disorders (<xref ref-type="bibr" rid="B10">Guipaud et&#x20;al., 2018</xref>), and changes in cell structure (<xref ref-type="bibr" rid="B1">Abayomi et&#x20;al., 2009</xref>). Recently, increasing evidence has shown that damage to the microvascular endothelium of the intestine is also involved (<xref ref-type="bibr" rid="B23">Waddell et&#x20;al., 1999</xref>; <xref ref-type="bibr" rid="B30">Zimmerer et&#x20;al., 2008</xref>). <xref ref-type="bibr" rid="B24">Wang et&#x20;al. (2004)</xref> demonstrated that the expression of tissue factor (TF) and thrombin receptor increased in the intestinal vascular endothelial cells of rats after radiotherapy, and intervention with hirudin and thrombin inhibitors showed a significant protective effect against intestinal radiation toxicity. TF is rarely present in blood circulation or in contact with circulating blood; indeed, it is exposed to the peripheral circulating blood only when the integrity of the vessel wall is compromised, in order to activate the cascade of blood coagulation (<xref ref-type="bibr" rid="B12">Herkert et&#x20;al., 2002</xref>). Thus, high expression of TF may induce microthrombus formation, ischemia, and disorder of the intestinal microcirculation system, which may be an important pathological mechanism for the persistence of&#x20;RE.</p>
<p>Radiation therapy leads to the production of reactive oxygen species and endogenous ligands such as alarmins, which further activate Toll-like receptor 4 (TLR4), and, subsequently, the apoptosis signaling kinase 1 (ASK1)/NF-&#x3ba;B-based inflammatory pathway (<xref ref-type="bibr" rid="B25">Wang et&#x20;al., 2019</xref>). Inhibition of the MAPK pathway can reduce the expression of TF induced by lipopolysaccharide (LPS) in monocytes and endothelial cells (<xref ref-type="bibr" rid="B3">Chen et&#x20;al., 2020</xref>). In addition, activation of the transcription factor NF-&#x3ba;B is necessary for maximizing TF expression (<xref ref-type="bibr" rid="B18">Oeth et&#x20;al., 1994</xref>; <xref ref-type="bibr" rid="B16">Mackman, 1996</xref>). As the upstream core factor of MAPK, ASK1 plays an important role in upregulating the expression and activity of TF (<xref ref-type="bibr" rid="B15">Mackman et&#x20;al., 1991</xref>; <xref ref-type="bibr" rid="B4">Chu et&#x20;al., 2001</xref>). Therefore, inhibiting the TLR-4/ASK-1/TF signaling pathway may be an effective way to alleviate RE. Considering the serious liver toxicity of TLR-4 inhibitors, such as eritoran (E5564) and TAK242, there is an urgent need to find a safe and effective drug or a new treatment method to inhibit TLR4 signaling.</p>
<p>TAM receptors (TYRO3, Axl, and Mer) belong to the receptor tyrosine kinase family. In the inflammatory self-regulation cycle, the activation of Axl signaling blocks the pro-inflammatory pathway, inducing transcription of anti-inflammatory inhibitors of cytokine signaling protein 3 (SOCS3) to inhibit the TLR signaling pathway (<xref ref-type="bibr" rid="B20">Rothlin et&#x20;al., 2007</xref>). TAM receptor activation is inseparable from the binding of the growth arrest-specific gene 6 (Gas6). It has been reported that overexpression of Gas6 could inhibit the production of proinflammatory factors in the synovium, and immunohistochemical results have shown that the SOCS3 protein has a corresponding increasing trend (<xref ref-type="bibr" rid="B21">van den Brand et&#x20;al., 2013</xref>). Paeoniflorin (PF) is a monoterpenoid glucoside, which has been widely used for its anti-inflammatory, hypoglycemic, and cognitive-enhancing properties, as well as other clinical medicinal values (<xref ref-type="bibr" rid="B28">Zhang and Wei, 2020</xref>). Our previous studies have confirmed that PF could significantly promote the expression of SOCS3&#x20;<italic>in vivo</italic> or <italic>in&#x20;vitro</italic>, inhibit ASK1 expression, reduce neuroinflammation, and relieve neuropathic pain (<xref ref-type="bibr" rid="B7">Frob&#xf8;se et&#x20;al., 2006</xref>). Thus, we speculated that PF may upregulate the Axl/SOCS3 axis to reduce inflammation and TF expression to alleviate&#x20;RE.</p>
<p>Here, we provide the first evidence that PF could alleviate RE by activating the Axl/SOCS3 axis to reduce intestinal inflammation and ischemia.</p>
</sec>
<sec sec-type="materials|methods" id="s2">
<title>Materials and Methods</title>
<sec id="s2-1">
<title>Animals and Treatments</title>
<p>Establishment of the RE model: Healthy male C57BL/6 mice weighing 18&#x2013;25&#xa0;g (4&#x2013;6&#xa0;weeks of age) were anesthetized by intraperitoneal (i.p.) injection of pentobarbital (50&#xa0;mg/kg). The mice received a single irradiation in the entire abdomen under the 6-MV electron line. The irradiation range was from the xiphoid to the pubic symphysis, the distance from the skin was 10&#xa0;cm, the dose rate was 260&#x2013;300&#xa0;MU/min, and the total amount of radiation was 14&#xa0;Gy. After irradiation, the mice were returned to the animal room for normal feeding.</p>
</sec>
<sec id="s2-2">
<title>Histological Analysis</title>
<p>On days 0, 2, 4, and 6, the colon of mice in each group was removed, and the colon tissues were completely separated and photographed. The filling degree of the colon, intestinal contents, and the thickness of the intestinal wall were observed with the naked eye to determine the degree of intestinal injury. At the same time, the length of the colon was measured. Samples were fixed in 4% paraformaldehyde at 4&#xb0;C overnight, transferred to sucrose (0.3&#xa0;g&#xa0;ml<sup>&#x2212;1</sup>), and stored at 4&#xb0;C. The samples were then embedded using conventional techniques. Sections of 5&#xa0;&#x3bc;m were cut and stained with hematoxylin and eosin (H&#x26;E) to observe for changes in the villi, goblet cells, and crypt of intestinal mucosa.</p>
</sec>
<sec id="s2-3">
<title>Cell Culture</title>
<p>RAW264.7 cells (ATCC number: TIB-71) were maintained in Dulbecco&#x2019;s modified Eagle&#x2019;s medium (DMEM, Gibco) supplemented with 10% (<italic>v</italic>/<italic>v</italic>) fetal bovine serum (FBS, Gibco) under humidified 5% CO<sub>2</sub> at 37&#xb0;C. Human umbilical vein endothelial cells (HUVEC) (KeyGen, KG419) were maintained in EBM-2 medium (Lonza) supplemented with SingleQuot Bullet Kit (Lonza) under humidified 5% CO<sub>2</sub> at 37&#xb0;C. For the LPS model, the cells were inoculated in a six-well plate and treated with different concentrations of PF 24&#xa0;h later (10<sup>&#x2212;4</sup>, 10<sup>&#x2212;5</sup>, 10<sup>&#x2212;6</sup>, and 10<sup>&#x2212;7</sup>&#xa0;M), 4&#xa0;h before stimulation with LPS (Sigma, 1&#xa0;&#x3bc;g/ml), and 12&#xa0;h after stimulation with LPS, the protein of cells was extracted from the six-well&#x20;plate.</p>
</sec>
<sec id="s2-4">
<title>Intestinal Blood Flow Measurement</title>
<p>The intestinal blood flow was measured using laser Doppler flowmetry. Specifically, a computer-controlled optical scanner was used to direct a low-power laser beam over the exposed intestine. The mice were placed on a thermostatic table, an incision of approximately 1&#xa0;cm was cut at the midline of the abdominal cavity, and a segment of the mesentery of the colon was selected and placed on a gel containing normal saline. Concurrently, the scanner head was positioned parallel to the exposed intestine at a distance of approximately 20&#xa0;cm. Subsequently, a color-coded image that denoted the specific relative perfusion level was displayed on the video monitor. Blood flow values were recorded and measured using the Moor FLPIR V40 program (Gene and I Scientific.&#x20;Ltd.).</p>
</sec>
<sec id="s2-5">
<title>Western Blotting</title>
<p>Samples were collected and lysed using lysis buffer supplemented with protease inhibitors. Proteins were fractionated by SDS-PAGE and transferred to polyvinylidene fluoride membranes. Subsequently, the membranes were soaked in blocking buffer for 2&#xa0;h at room temperature. After blocking, the cells were incubated overnight at 4&#xb0;C with antibodies against TF (Santa Cruz Biotechnology), SOCS3 (Cell Signaling Technology), p-ASK1 (Santa Cruz Biotechnology), and &#x3b2;-actin (Santa Cruz Biotechnology). The blots were then incubated with secondary antibodies (Cell Signaling Technology). ImageJ software (Rawak Software Inc. Germany) was used for densitometric analyses.</p>
</sec>
<sec id="s2-6">
<title>Statistical Analysis</title>
<p>Statistical analyses were performed using Prism 6.0 (GraphPad). The unpaired Student&#x2019;s <italic>t</italic>-test was used to analyze the differences between the two groups. Alteration of protein expression and behavioral responses were tested with one-way analysis of variance (ANOVA), and the differences in latency over time among groups were tested with two-way ANOVA, followed by Bonferroni&#x2019;s <italic>post</italic>-<italic>hoc</italic> tests. Error bars in all figures represent the mean&#xa0;&#xb1;&#xa0;standard error of the mean. The number of replicates and statistical tests are reported in all figure captions.</p>
</sec>
</sec>
<sec sec-type="results" id="s3">
<title>Results</title>
<sec id="s3-1">
<title>Radiation Induces Intestinal Inflammation and Slow Blood Flow in Mice</title>
<p>First, we investigated the survival rate, intestinal inflammation, and blood flow in mice exposed to radiation. Compared with the control group, radiation significantly decreased the survival rate of mice by as much as 30% on the 6th day (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). As shown in <xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>, compared with the control group, H&#x26;E staining showed that the mucous membrane was severely damaged, the cells were arranged disorderly, and the glands became smaller and began to atrophy in the mouse colon on the 2nd day after 14-Gy irradiation. On the 6th day after irradiation, edema occurred, a large number of inflammatory cells infiltrated the colon, and the original structure of the intestine was compromised. Laser Doppler flowmetry was used to determine the blood flow of the intestinal tract of mice (<xref ref-type="fig" rid="F1">Figures 1C,D</xref>); radiation markedly decreased the blood flow of the intestinal tract on the 4th and 6th day after exposure.</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Radiation induces intestinal inflammation and slow blood flow in mice. <bold>(A)</bold> Survival rate of mice administered with radiation and those that were not. The implemented procedures were as follows: a single irradiation of the lower abdomen of mice with a 6-MV electronic wire; the irradiation range was from the xiphoid to pubic symphysis; the distance from the skin was 10&#xa0;cm; the dose rate was 260&#x2013;300&#xa0;MU/min; the total amount of irradiation was 14&#xa0;Gy; and the survival rate of mice was calculated during the disease process (<italic>n</italic>&#x20;&#x3d; 10 per group). Mice were exposed to 14-Gy radiation and were returned to the animal room for normal feeding during the next days. All mice were sacrificed at different time points (days 0, 2, 4, and 6). <bold>(B)</bold> Sections of colonic tissues were separated and stained with hematoxylin and eosin staining to observe the structure of the intestinal wall (<italic>n</italic>&#x20;&#x3d; 4 per group). The photos were observed with a confocal laser scanning microscope at &#xd7;50 and &#xd7;200 magnifications. <bold>(C,D)</bold> Intestinal blood flow was detected by laser Doppler and was then calculated (<italic>n</italic>&#x20;&#x3d; 5 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05 and &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 vs. control group.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g001.tif"/>
</fig>
<p>These data suggest that radiation could significantly increase intestinal inflammation, compromise intestinal structure, cause poor intestinal blood circulation, and decrease the survival rate of&#x20;mice.</p>
</sec>
<sec id="s3-2">
<title>PF Reduces Mortality and Improves RE in Mice Exposed to Radiation</title>
<p>To study the effect of PF on RE in mice, different doses of PF were administered intraperitoneally. As shown in <xref ref-type="fig" rid="F2">Figure&#x20;2A</xref>, PF significantly decreased the mortality rate of mice exposed to radiation, especially at a dose of 90&#xa0;mg/kg, which was a better outcome than that obtained with the positive control drug dexamethasone (DXM, 1.25&#xa0;mg/kg, i.p.). After radiation, the appetite of the mice decreased. It was found that the weight of the mice in the radiation model group decreased compared to that of the control group, which presented a greater improvement with PF (90&#xa0;mg/kg, i.p.) treatment than with DXM treatment (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>). We further measured the structure and blood flow of the colon using H&#x26;E staining and laser Doppler flowmetry. As shown in <xref ref-type="fig" rid="F2">Figure&#x20;2C</xref>, compared with the radiation group on the 2nd and 6th days, PF (90&#xa0;mg/kg, i.p.) decreased mucous membrane damage, recovered gland size, and reduced edema and inflammatory cell infiltration in the colon. PF (90&#xa0;mg/kg, i.p.) also increased the blood flow in the colon compared to that observed in the radiation group on the 4th and 6th days (<xref ref-type="fig" rid="F2">Figures 2D,E</xref>). These data suggest that PF could markedly improve RE and increase the survival rate of mice after radiation.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>Paeoniflorin reduces mortality and improves radiation enteritis in mice exposed to radiation. Saline, dexamethasone, and different doses of paeoniflorin (PF) (30, 60, and 90&#xa0;mg/kg) were injected intraperitoneally into the mice of the respective groups 2&#xa0;h after they were exposed to 14-Gy radiation on the 1st day. Saline, dexamethasone, and PF were then administered every 24&#xa0;h from the 2nd to the 14th day. <bold>(A)</bold> The survival rate of mice was calculated during the disease process (<italic>n</italic>&#x20;&#x3d; 10 per group). <bold>(B)</bold> The body weight changes during the disease process (<italic>n</italic>&#x20;&#x3d; 6 per group). <bold>(C)</bold> Sections of colonic tissues were separated and stained with hematoxylin and eosin staining (<italic>n</italic>&#x20;&#x3d; 4 per group). The photos were observed with a confocal laser scanning microscope at &#xd7;50 and &#xd7;200 magnifications. <bold>(D,E)</bold> The intestinal blood flow was detected by laser Doppler and was then calculated (<italic>n</italic>&#x20;&#x3d; 5 per group). &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01 and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 vs. control group; <sup>&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.05 and <sup>&#x23;&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.001 vs. 14-Gy radiation &#x2b; saline group; <sup>&#x26;&#x26;&#x26;</sup>
<italic>p</italic>&#x20;&#x3c; 0.001 vs. 14-Gy radiation &#x2b; saline&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g002.tif"/>
</fig>
</sec>
<sec id="s3-3">
<title>PF Reduces Intestinal Injury and TF Expression <italic>via</italic> Inhibiting ASK1 Activity</title>
<p>The feces, diluted feces, and water samples of the mice were easy to distinguish and observe. As shown in <xref ref-type="fig" rid="F3">Figure&#x20;3A</xref>, we collected the colon of the mice and found that, in the control group, colons had black and granular contents in the intestinal tract with a normal formation of feces. Compared with the control group, the colon length was significantly shortened, and a yellow water sample appeared in the colon of mice exposed to radiation. On day 6 after radiation, PF (90&#xa0;mg/kg, i.p.) clearly improved intestinal length and content status.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>PF reduces intestinal injury and TF expression <italic>via</italic> inhibiting ASK1 activity. PF (90&#xa0;mg/kg, intraperitoneally) was administered to radiation mice, and mice of each group were sacrificed at different time points (days 0, 2, 4, and 6). <bold>(A)</bold> Macroscopic images were observed, and the length of the colon from each group was measured and calculated (<italic>n</italic>&#x20;&#x3d; 4 per group). <bold>(B&#x2013;D)</bold> Tissue factor (TF), p-apoptosis signaling kinase 1 (p-ASK1), and suppressor of cytokine signaling 3 (SOCS3) expression in the colon was determined by western blotting on the 6th day (<italic>n</italic>&#x20;&#x3d; 3 per group). <bold>(E,F,H,I)</bold> The intestinal blood flow was detected by laser Doppler and was then calculated on the 6th day (<italic>n</italic>&#x20;&#x3d; 5 per group). NQDI1 (4&#xa0;mg/kg, i.p.) was administered 0.5&#xa0;h before PF treatment. Mice were administered with thromboplastin (2.5&#xa0;&#x3bc;g/kg, intravenously) injection within 20&#xa0;s after PF treatment on the 6th day. <bold>(G)</bold> Sections of colonic tissues were separated and stained with hematoxylin and eosin on the 6th day (<italic>n</italic>&#x20;&#x3d; 4 per group). &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 vs. control group; <sup>&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.01 vs. 14-Gy radiation group; <sup>$$$</sup>
<italic>p</italic>&#x20;&#x3c; 0.001 vs. 14-Gy radiation &#x2b; PF&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g003.tif"/>
</fig>
<p>We further examined the expression of the coagulation factor TF related to microthrombus formation. Colon samples on day 6, administrated with or without PF, were collected to evaluate for indicators of thrombosis and further verified the effects of PF in mice. Compared with the control group, radiation increased TF expression, which was subsequently decreased by PF treatment (<xref ref-type="fig" rid="F3">Figure&#x20;3B</xref>). In addition, we measured the expression of the upstream target protein, ASK1. As shown in <xref ref-type="fig" rid="F3">Figure&#x20;3C</xref>, the phosphorylation of ASK1 increased after radiotherapy, whereas PF significantly reduced ASK1 phosphorylation. We also found that PF could increase the expression of SOCS3 (&#x201c;inflammation brake&#x201d;) in the intestinal tract of mice (<xref ref-type="fig" rid="F3">Figure&#x20;3D</xref>).</p>
<p>Furthermore, the ASK1 inhibitor NQDI1 was used to investigate the role of ASK1 in the progression of RE. Compared with the radiation group, NQDI1 (4&#xa0;mg/kg, i.p.) (<xref ref-type="bibr" rid="B14">Ma et&#x20;al., 2020</xref>) increased the blood flow of the colon and improved intestinal ischemia in comparison to those found in the radiation group (<xref ref-type="fig" rid="F3">Figures 3E, F</xref>). NQDI1 also significantly decreased mucous membrane damage, recovered gland size, and reduced edema in the colon of mice (<xref ref-type="fig" rid="F3">Figure&#x20;3G</xref>).</p>
<p>We further verified the importance of TF in the development of RE. Thromboplastin (2.5&#xa0;&#x3bc;g/kg, intravenously, corresponding to a dose of 2.5&#xa0;&#x3bc;g/kg TF) (<xref ref-type="bibr" rid="B26">Wyseure et&#x20;al., 2015</xref>) was used to set as the TF-related rescue experiments. As shown in <xref ref-type="fig" rid="F3">Figures 3H,I</xref>, the protective effect of PF on intestinal blood flow was cancelled by thromboplastin.</p>
<p>These data suggested that PF could upregulate SOCS3 expression and inhibit the ASK1/TF axis to relieve intestinal injury.</p>
</sec>
<sec id="s3-4">
<title>PF Induces SOCS3 Expression and Inhibits ASK1/TF Axis <italic>In Vitro</italic>
</title>
<p>To explore the mechanism of PF on the expression of SOCS3, mouse monocyte macrophages (RAW264.7 cells) and HUVEC were used for <italic>in&#x20;vitro</italic> experiments. As shown in <xref ref-type="fig" rid="F4">Figures 4A</xref>, <xref ref-type="fig" rid="F5">5A</xref>, PF induced the expression of SOCS3 in RAW264.7 and HUVEC, especially at concentrations of 10<sup>&#x2212;6</sup> and 10<sup>&#x2212;5</sup>&#xa0;M.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>PF induces SOCS3 expression to inhibit the expression of p-ASK1 and TF in RAW264.7 cells. <bold>(A)</bold> RAW264.7 cells were treated with different doses of PF (10<sup>&#x2212;8</sup>, 10<sup>&#x2212;7</sup>, 10<sup>&#x2212;6</sup>, 10<sup>&#x2212;5</sup>, and 10<sup>&#x2212;4</sup>&#xa0;M) for 4&#xa0;h, and the expression of SOCS3 was determined by western blotting. <bold>(B,C)</bold> Different doses of PF were pre-administered for 4&#xa0;h, and LPS (1&#xa0;&#x3bc;g/ml) was then administered for 12&#xa0;h; the expressions of p-ASK1, ASK1, and TF were determined by western blotting. <bold>(D)</bold> ASK1 inhibitor NQDI-1 (600&#xa0;nM) was pre-administered for 0.5&#xa0;h, and LPS (1&#xa0;&#x3bc;g/ml) was then administered for 12&#xa0;h; the expression of TF was determined by western blotting. <bold>(E)</bold> The expression of SOCS3 after PF (10<sup>&#x2212;6</sup>&#xa0;M) administration with or without LPS (1&#xa0;&#x3bc;g/ml). <italic>n</italic>&#x20;&#x3d; 3 per group; &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 vs. control group; <sup>&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.01 and <sup>&#x23;&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.001 vs. LPS&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g004.tif"/>
</fig>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>PF induces SOCS3 expression to inhibit the expression of p-ASK1 and TF in human umbilical vein endothelial cells (HUVEC). <bold>(A)</bold> HUVEC were treated with different doses of PF (10<sup>&#x2212;8</sup>, 10<sup>&#x2212;7</sup>, 10<sup>&#x2212;6</sup>, 10<sup>&#x2212;5</sup>, and 10<sup>&#x2212;4</sup>&#xa0;M) for 4&#xa0;h; the expression of SOCS3 was determined by western blotting. <bold>(B,C)</bold> Different doses of PF were pre-administered for 4&#xa0;h, and LPS (1&#xa0;&#x3bc;g/ml) was then administered for 12&#xa0;h; the expressions of p-ASK1, ASK1, and TF were determined by western blotting. <bold>(D)</bold> NQDI-1 (600&#xa0;nM) was pre-administered for 0.5&#xa0;h, and LPS (1&#xa0;&#x3bc;g/ml) was then administered for 12&#xa0;h; the expression of TF was determined by western blotting. <bold>(E)</bold> The expression of SOCS3 after PF (10<sup>&#x2212;6</sup>&#xa0;M) administration with or without LPS (1&#xa0;&#x3bc;g/ml). <italic>n</italic>&#x20;&#x3d; 3 per group; &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 vs. control group; and <sup>&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.01, and <sup>&#x23;&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.001 vs. LPS&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g005.tif"/>
</fig>
<p>RAW264.7 and HUVEC were treated with different doses of PF for 4&#xa0;h and then treated with LPS (1&#xa0;&#x3bc;g/ml) for 12&#xa0;h. As shown in <xref ref-type="fig" rid="F4">Figures 4B, C</xref>, <xref ref-type="fig" rid="F5">5B, C</xref>, LPS significantly increased the expression of p-ASK1 and TF in RAW264.7 and HUVEC, which were reduced by PF treatment (10<sup>&#x2212;6</sup>, 10<sup>&#x2212;5</sup>, and 10<sup>&#x2212;4</sup>&#xa0;M). The effect of PF on TF expression was mimicked by the ASK1 inhibitor NQDI-1 (<xref ref-type="fig" rid="F4">Figures 4D</xref>, <xref ref-type="fig" rid="F5">5D</xref>). To verify the effect of PF on SOCS3 expression in the inflammatory state, data showed that PF induced the expression of SOCS3 even in the presence of LPS (<xref ref-type="fig" rid="F4">Figures 4E</xref>,&#x20;<xref ref-type="fig" rid="F5">5E</xref>).</p>
<p>These data suggested that ASK1 is an important upstream regulator of LPS-induced TF production. PF upregulates SOCS3 expression to inhibit the ASK1/TF&#x20;axis.</p>
</sec>
<sec id="s3-5">
<title>PF Activates Gas6/Axl Signaling to Induce SOCS3 Expression</title>
<p>We further explored the mechanism by which PF induces SOCS3 expression. The Axl receptor is an upstream regulator of SOCS3 (<xref ref-type="bibr" rid="B22">van der Meer et&#x20;al., 2014</xref>). As shown in <xref ref-type="fig" rid="F6">Figures 6A,D</xref>, compared with the control group, PF significantly increased the phosphorylation of Axl in RAW264.7 and HUVEC. We further detected the expression of Axl ligand Gas6. As shown in <xref ref-type="fig" rid="F6">Figures 6B,C,E</xref>, PF also significantly increased the level of Gas 6 protein and mRNA in RAW264.7 and HUVEC, which was consistent with the expression of <italic>p</italic>-Axl.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>PF promotes SOCS3 expression <italic>via</italic> activating Gas6/Axl axis. The expression of <italic>p</italic>-Axl was determined by western blotting in RAW264.7 cells <bold>(A)</bold> and human umbilical vein endothelial cells (HUVEC) <bold>(D)</bold>. The level of Gas6 protein and mRNA was measured in the supernatant of RAW264.7 cells <bold>(B,C)</bold> and HUVEC <bold>(E,F)</bold>. RAW264.7 and HUVEC were administered with PF (10<sup>&#x2212;6</sup>&#xa0;M) for 4&#xa0;h. The expressions of <italic>p</italic>-Axl <bold>(G)</bold> and Gas6&#x20;<bold>(H)</bold> after PF (10<sup>&#x2212;6</sup>&#xa0;M) administration with or without LPS (1&#xa0;&#x3bc;g/ml) in Raw264.7 cells. <bold>(I)</bold> The expression of SOCS3, p-ASK1, and ASK1 was measured in Raw264.7 cells after Axl knockdown. <italic>n</italic>&#x20;&#x3d; 3 per group; &#x2a;<italic>p</italic>&#x20;&#x3c; 0.05, &#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.01, and &#x2a;&#x2a;&#x2a;<italic>p</italic>&#x20;&#x3c; 0.001 vs. control group; <sup>&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.05, <sup>&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.01, and <sup>&#x23;&#x23;&#x23;</sup>
<italic>p</italic>&#x20;&#x3c; 0.001 vs. LPS group; <sup>$$</sup>
<italic>p</italic>&#x20;&#x3c; 0.01 vs. LPS &#x2b; PF&#x20;group.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g006.tif"/>
</fig>
<p>In addition, LPS was used to establish an inflammatory cell model. Compared with the LPS group, PF significantly increased the expression of Gas 6 and <italic>p</italic>-Axl in the LPS &#x2b; PF group in Raw264.7 cells (<xref ref-type="fig" rid="F6">Figures 6G,H</xref>). We then verified the importance of Axl by using its siRNA to measure the expression of SOCS3 and p-ASK1 in Raw264.7 cells. As shown in <xref ref-type="fig" rid="F6">Figure&#x20;6I</xref>, PF markedly increased the expression of SOCS3 and decreased the phosphorylation of ASK1, which were eliminated by Axl knockout in Raw264.7&#x20;cells.</p>
<p>These data suggest that PF induces SOCS3 expression and inhibits ASK1 phosphorylation by activating the Axl receptor.</p>
</sec>
</sec>
<sec sec-type="discussion" id="s4">
<title>Discussion</title>
<p>The major findings of this study are as follows: 1) radiation induces intestinal inflammation and slow blood flow in mice; 2) PF reduces mortality and improves RE in irradiated mice; 3) PF reduces radiation-induced intestinal injury and TF expression by decreasing ASK1 phosphorylation; 4) PF induces SOCS3 expression and inhibits the ASK1/TF axis <italic>in&#x20;vitro</italic>; and 5) PF activates Gas6/Axl signaling to induce SOCS3 expression.</p>
<p>RE is a high-incidence complication in radiotherapy for patients with abdominal or pelvic cancer (<xref ref-type="bibr" rid="B19">Potten, 1990</xref>). Although the precision of chemotherapy has significantly improved with advancements in technology (<xref ref-type="bibr" rid="B2">Abbaso&#x11f;lu et&#x20;al., 2006</xref>), enteritis-related injuries caused by radiotherapy cannot currently be avoided and&#x20;cured.</p>
<p>In this study, we first established the mouse RE model according to the study by <xref ref-type="bibr" rid="B9">Goldstein et&#x20;al. (1976</xref>), with a total radiation dose of 14&#xa0;Gy. We found that the mortality of mice exposed to radiation increased significantly over time (<xref ref-type="fig" rid="F1">Figure&#x20;1A</xref>). Intestinal edema, infiltration of a large number of inflammatory cells, and severe intestinal structural damage were found in the colorectum after radiotherapy (<xref ref-type="fig" rid="F1">Figure&#x20;1B</xref>), resulting in more severe weight loss in mice during the disease process (<xref ref-type="fig" rid="F2">Figure&#x20;2B</xref>).</p>
<p>The effects of intestinal blood flow on RE have rarely been reported. <xref ref-type="bibr" rid="B24">Wang et&#x20;al. (2004)</xref> found that the expression of TF was increased in the intestinal tract of rats that received radiotherapy and that hirudin and the platelet inhibitor clopidogrel (<xref ref-type="bibr" rid="B5">Dri&#xe1;k et&#x20;al., 2008</xref>) could alleviate RE by inhibiting platelet aggregation and reducing gastrointestinal damage. However, presently, there is no direct evidence supporting that poor intestinal blood circulation after radiotherapy is involved in RE. To the best of our knowledge, we were the first to use laser Doppler flowmetry to measure intestinal blood flow in mice. The results showed that the intestinal blood flow rate of mice decreased significantly on the sixth day after radiotherapy (<xref ref-type="fig" rid="F2">Figure&#x20;2D</xref>) and that the ASK1/TF signaling pathway was significantly activated in the colon (<xref ref-type="fig" rid="F3">Figure&#x20;3</xref>), indicating that local ischemia and hypoxia caused slow blood flow in the intestine.</p>
<p>In our previous study on the pathogenesis of chemotherapy-induced enteritis, we found that chemotherapy could cause microthrombi in the local circulation of intestinal blood vessels (<xref ref-type="bibr" rid="B27">Yu et&#x20;al., 2020</xref>). In this study, there were many similarities between RE and chemotherapy-related enteritis, such as the observed significant reduction in intestinal blood flow after radiotherapy. It is noteworthy that the loss of a large number of intestinal collagen fibers within a short period of time completely comprised the intestinal function, with the severe inflammatory response leading to an increased vulnerability of the intestinal tract. In these conditions, not only there is aseptic inflammation induced by post-radiation apoptosis of vascular endothelial cells but also bacteriological inflammation induced by an impaired intestinal barrier resulting from the presence of bacteria in the blood, which brought further damage to the blood vessels; moreover, since the local ischemic microenvironment caused by clotting thrombi can further aggravate inflammation, it is reasonable to speculate that, in all enteritis models, RE is more likely to lethally compromise the intestinal tract, which is consistent with our expectation, and their mutual action jointly mediates the important mechanism of&#x20;RE.</p>
<p>Currently, we are exploring alternatives to find potential treatments for RE in clinical practice. PF, a pinane monoterpene bitter glycoside, differs from red peony and white peony, a traditional Chinese medicine. This compound has analgesic, anti-inflammatory, antipyretic, and antispasmodic functions and has the advantage of presenting very low toxicity (<xref ref-type="bibr" rid="B11">He and Dai, 2011</xref>). At present, the effects of PF on the promotion of blood circulation and removal of blood stasis, along with its anti-inflammatory and anti-thrombotic effects, are its most relevant therapeutic properties (<xref ref-type="bibr" rid="B13">Jorch and Kubes, 2017</xref>; <xref ref-type="bibr" rid="B6">Fan et&#x20;al., 2018</xref>). Our data showed that PF reduced mortality and improved weight loss in mice after radiotherapy in a dose-dependent manner (<xref ref-type="fig" rid="F2">Figures 2A,B</xref>). The data from H&#x26;E staining and laser Doppler flowmetry indicated that PF could alleviate the inflammatory response and improve slow blood flow in mice after radiotherapy (<xref ref-type="fig" rid="F2">Figures 2C,D</xref>). Indeed, PF has been shown to upregulate SOCS3 expression to reduce neuroinflammation and neuropathic pain by inhibiting ASK1 activity (<xref ref-type="bibr" rid="B29">Zhou et&#x20;al., 2019</xref>). Here, we demonstrated that PF could induce SOCS3 expression and inhibit ASK1 phosphorylation (<xref ref-type="fig" rid="F3">Figures 3C,D</xref>, <xref ref-type="fig" rid="F4">4A</xref>, <xref ref-type="fig" rid="F5">5A</xref>) <italic>in vivo</italic> and <italic>in&#x20;vitro</italic>. More importantly, for the first time, we proposed a new mechanism of PF, involving the upregulation of SOCS3 expression, in which the upstream Gas6/Axl axis was activated by PF (<xref ref-type="fig" rid="F6">Figure&#x20;6</xref>).</p>
<p>In conclusion, our findings suggest that slow blood flow caused by local microthrombi and inflammation in the intestine may be the core mechanism of RE. Furthermore, PF activated the Gas6/p-Axl/SOCS3 axis to alleviate RE by inhibiting p-ASK1 and TF expression (<xref ref-type="fig" rid="F7">Figure&#x20;7</xref>).</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>Proposed hypothesis on the mechanisms underlying the alleviating effects of PF on radiation enteritis. The TF released from vascular endothelial cells and macrophages after radiation caused thrombosis and microcirculation disorders. PF inhibits coagulation by promoting growth arrest-specific gene 6 release and <italic>p</italic>-Axl activation to upregulate SOCS3, subsequently reducing the expression of TF.</p>
</caption>
<graphic xlink:href="fphar-13-743708-g007.tif"/>
</fig>
</sec>
</body>
<back>
<sec id="s5">
<title>Data Availability Statement</title>
<p>The raw data supporting the conclusion of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s6">
<title>Ethics Statement</title>
<p>The animal studies, reviewed and approved by animal care and husbandry, were carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals (Ministry of Science and Technology of China, 2006) and the Nanjing Medical University Animal Care and Use Committee (NMJU-ACUC). During the experiments, animal pain and animal usage were minimized.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>LS, FH, YG, HY, and XT: methodology and software (performing the experiments and analyzing the results). LS, RJ, YG, LC and HK: methodology (carrying out of the animal experiments, gelatin zymography, and H&#x26;E staining). JM, LS, and WF: methodology (carrying out the western blotting analysis). XZ, XH, JM, CM, YY, and JJ: methodology (helping in carrying out the cell cultures). XT, XZ, XH, JM, FH, and MJ helped revise the manuscript. JM, LH, W-TL, and MY: conceptualization, methodology, and writing&#x2014;original draft, review, and editing. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s8">
<title>Funding</title>
<p>This work was supported by grants from the National Natural Science Foundation of China (81971047), Major Project of &#x201c;Science and Technology Innovation Fund&#x201d; of Nanjing Medical University (2017NJMUCX004), Key R&#x26;D Program (Social Development) Project of Jiangsu Province (BE2019732). Nanjing special fund for health science and technology development (YKK19170). General Projects of Traditional Chinese Medicine Administration of Jiangsu Province (YB201821). Class A key project of Health Commission of Jiangsu Province (ZDA2020020). Key Natural Science Project of Bengbu Medical College (2020byzd387, 2020byzd388). Yangzhou City&#x2019;s 13th Five-Year Plan for &#x201c;Ke Jiao Qiang Wei&#x201d; (Grant no.LJRC20181). Key Laboratory of Jiangsu Province (XZSYSKF202101). Lianyungang Science and Technology Plan (social development) project (SF2122).</p>
</sec>
<sec sec-type="COI-statement" id="s9">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="disclaimer" id="s10">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abayomi</surname>
<given-names>J.&#x20;C.</given-names>
</name>
<name>
<surname>Kirwan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Hackett</surname>
<given-names>A. F.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Coping Mechanisms Used by Women in an Attempt to Avoid Symptoms of Chronic Radiation Enteritis</article-title>. <source>J.&#x20;Hum. Nutr. Diet.</source> <volume>22</volume> (<issue>4</issue>), <fpage>310</fpage>&#x2013;<lpage>316</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-277X.2009.00963.x</pub-id> </citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abbaso&#x11f;lu</surname>
<given-names>S. D.</given-names>
</name>
<name>
<surname>Erbil</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Eren</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Giri&#x15f;</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Barbaros</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Y&#xfc;cel</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>The Effect of Heme Oxygenase-1 Induction by Octreotide on Radiation Enteritis</article-title>. <source>Peptides</source> <volume>27</volume> (<issue>6</issue>), <fpage>1570</fpage>&#x2013;<lpage>1576</lpage>. <pub-id pub-id-type="doi">10.1016/j.peptides.2005.11.012</pub-id> </citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Lao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>SENP3 in Monocytes/macrophages Up-Regulates Tissue Factor and Mediates Lipopolysaccharide-Induced Acute Lung Injury by Enhancing JNK Phosphorylation</article-title>. <source>J.&#x20;Cel Mol Med</source> <volume>24</volume> (<issue>10</issue>), <fpage>5454</fpage>&#x2013;<lpage>5462</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.15199</pub-id> </citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z. G.</given-names>
</name>
<name>
<surname>Walton</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Seto</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2001</year>). <article-title>Involvement of MAPK Activation in Bacterial Endotoxin-Inducible Tissue Factor Upregulation in Human Monocytic THP-1 Cells</article-title>. <source>J.&#x20;Surg. Res.</source> <volume>101</volume> (<issue>1</issue>), <fpage>85</fpage>&#x2013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1006/jsre.2001.6271</pub-id> </citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dri&#xe1;k</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Osterreicher</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>V&#xe1;vrov&#xe1;</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Reh&#xe1;kov&#xe1;</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Vilasov&#xe1;</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Morphological Changes of Rat Jejunum after Whole Body Gamma-Irradiation and Their Impact in Biodosimetry</article-title>. <source>Physiol. Res.</source> <volume>57</volume> (<issue>3</issue>), <fpage>475</fpage>&#x2013;<lpage>479</lpage>. </citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Paeoniflorin Blocks the Proliferation of Vascular Smooth Muscle Cells Induced by Platelet-derived G-rowth factor-BB through ROS Mediated ERK1/2 and P38 Signaling Pathways</article-title>. <source>Mol. Med. Rep.</source> <volume>17</volume> (<issue>1</issue>), <fpage>1676</fpage>&#x2013;<lpage>1682</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.8093</pub-id> </citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frob&#xf8;se</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Groth R&#xf8;nn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Heding</surname>
<given-names>P. E.</given-names>
</name>
<name>
<surname>Mendoza</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Mandrup-Poulsen</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Suppressor of Cytokine Signaling-3 Inhibits Interleukin-1 Signaling by Targeting the TRAF-6/TAK1 Complex</article-title>. <source>Mol. Endocrinol.</source> <volume>20</volume> (<issue>7</issue>), <fpage>1587</fpage>&#x2013;<lpage>1596</lpage>. <pub-id pub-id-type="doi">10.1210/me.2005-0301</pub-id> </citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>G&#xe9;rard</surname>
<given-names>J.-P.</given-names>
</name>
<name>
<surname>Conroy</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Bonnetain</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bouch&#xe9;</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Chapet</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Closon-Dejardin</surname>
<given-names>M.-T.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Preoperative Radiotherapy with or without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203</article-title>. <source>Jco</source> <volume>24</volume> (<issue>28</issue>), <fpage>4620</fpage>&#x2013;<lpage>4625</lpage>. <pub-id pub-id-type="doi">10.1200/jco.2006.06.7629</pub-id> </citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Khoury</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thornton</surname>
<given-names>J.&#x20;J.</given-names>
</name>
</person-group> (<year>1976</year>). <article-title>Treatment of Chronic Radiation Enteritis and Colitis with Salicylazosulfapyridine and Systemic Corticosteroids. A Pilot Study</article-title>. <source>Am. J.&#x20;Gastroenterol.</source> <volume>65</volume> (<issue>3</issue>), <fpage>201</fpage>&#x2013;<lpage>208</lpage>. </citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guipaud</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Jaillet</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cl&#xe9;ment-Colmou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Fran&#xe7;ois</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Supiot</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Milliat</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The Importance of the Vascular Endothelial Barrier in the Immune-Inflammatory Response Induced by Radiotherapy</article-title>. <source>Br. J.&#x20;Radiol.</source> <volume>91</volume> (<issue>1089</issue>), <fpage>20170762</fpage>. <pub-id pub-id-type="doi">10.1259/bjr.20170762</pub-id> </citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>He</surname>
<given-names>D. Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Anti-inflammatory and Immunomodulatory Effects of Paeonia Lactiflora pall., a Traditional Chinese Herbal Medicine</article-title>. <source>Front. Pharmacol.</source> <volume>2</volume>, <fpage>10</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2011.00010</pub-id> </citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herkert</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Diebold</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Brandes</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Hess</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Busse</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>G&#xf6;rlach</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2002</year>). <article-title>NADPH Oxidase Mediates Tissue Factor-dependent Surface Procoagulant Activity by Thrombin in Human Vascular Smooth Muscle Cells</article-title>. <source>Circulation</source> <volume>105</volume> (<issue>17</issue>), <fpage>2030</fpage>&#x2013;<lpage>2036</lpage>. <pub-id pub-id-type="doi">10.1161/01.cir.0000014611.28864.1e</pub-id> </citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jorch</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Kubes</surname>
<given-names>P.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>An Emerging Role for Neutrophil Extracellular Traps in Noninfectious Disease</article-title>. <source>Nat. Med.</source> <volume>23</volume> (<issue>3</issue>), <fpage>279</fpage>&#x2013;<lpage>287</lpage>. <pub-id pub-id-type="doi">10.1038/nm.4294</pub-id> </citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ma</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Rodrigues</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Chronic-plus-binge Alcohol Intake Induces Production of Proinflammatory mtDNA-Enriched Extracellular Vesicles and Steatohepatitis via ASK1/p38MAPK&#x3b1;-dependent Mechanisms</article-title>. <source>JCI Insight</source> <volume>5</volume> (<issue>14</issue>), <fpage>1</fpage>. <pub-id pub-id-type="doi">10.1172/jci.insight.136496</pub-id> </citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Brand</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Edgington</surname>
<given-names>T. S.</given-names>
</name>
</person-group> (<year>1991</year>). <article-title>Lipopolysaccharide-mediated Transcriptional Activation of the Human Tissue Factor Gene in THP-1 Monocytic Cells Requires Both Activator Protein 1 and Nuclear Factor Kappa B Binding Sites</article-title>. <source>J.&#x20;Exp. Med.</source> <volume>174</volume> (<issue>6</issue>), <fpage>1517</fpage>&#x2013;<lpage>1526</lpage>. <pub-id pub-id-type="doi">10.1084/jem.174.6.1517</pub-id> </citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mackman</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>1996</year>). <article-title>Regulation of Tissue Factor Gene Expression in Human Monocytic and Endothelial Cells</article-title>. <source>Haemostasis</source> <volume>26</volume> (<issue>Suppl. 1</issue>), <fpage>17</fpage>&#x2013;<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1159/000217234</pub-id> </citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modlin</surname>
<given-names>I. M.</given-names>
</name>
<name>
<surname>Kidd</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Latich</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Zikusoka</surname>
<given-names>M. N.</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>M. D.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Current Status of Gastrointestinal Carcinoids</article-title>. <source>Gastroenterology</source> <volume>128</volume> (<issue>6</issue>), <fpage>1717</fpage>&#x2013;<lpage>1751</lpage>. <pub-id pub-id-type="doi">10.1053/j.gastro.2005.03.038</pub-id> </citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oeth</surname>
<given-names>P. A.</given-names>
</name>
<name>
<surname>Parry</surname>
<given-names>G. C.</given-names>
</name>
<name>
<surname>Kunsch</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nantermet</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>C. A.</given-names>
</name>
<name>
<surname>Mackman</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>1994</year>). <article-title>Lipopolysaccharide Induction of Tissue Factor Gene Expression in Monocytic Cells Is Mediated by Binding of C-Rel/p65 Heterodimers to a Kappa B-like Site</article-title>. <source>Mol. Cel Biol</source> <volume>14</volume> (<issue>6</issue>), <fpage>3772</fpage>&#x2013;<lpage>3781</lpage>. <pub-id pub-id-type="doi">10.1128/mcb.14.6.3772</pub-id> </citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Potten</surname>
<given-names>C. S.</given-names>
</name>
</person-group> (<year>1990</year>). <article-title>A Comprehensive Study of the Radiobiological Response of the Murine (BDF1) Small Intestine</article-title>. <source>Int. J.&#x20;Radiat. Biol.</source> <volume>58</volume> (<issue>6</issue>), <fpage>925</fpage>&#x2013;<lpage>973</lpage>. <pub-id pub-id-type="doi">10.1080/09553009014552281</pub-id> </citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rothlin</surname>
<given-names>C. V.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zuniga</surname>
<given-names>E. I.</given-names>
</name>
<name>
<surname>Oldstone</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Lemke</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2007</year>). <article-title>TAM Receptors Are Pleiotropic Inhibitors of the Innate Immune Response</article-title>. <source>Cell</source> <volume>131</volume> (<issue>6</issue>), <fpage>1124</fpage>&#x2013;<lpage>1136</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2007.10.034</pub-id> </citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van den Brand</surname>
<given-names>B. T.</given-names>
</name>
<name>
<surname>Abdollahi-Roodsaz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vermeij</surname>
<given-names>E. A.</given-names>
</name>
<name>
<surname>Bennink</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Arntz</surname>
<given-names>O. J.</given-names>
</name>
<name>
<surname>Rothlin</surname>
<given-names>C. V.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Therapeutic Efficacy of Tyro3, Axl, and Mer Tyrosine Kinase Agonists in Collagen-Induced Arthritis</article-title>. <source>Arthritis Rheum.</source> <volume>65</volume> (<issue>3</issue>), <fpage>671</fpage>&#x2013;<lpage>680</lpage>. <pub-id pub-id-type="doi">10.1002/art.37786</pub-id> </citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van der Meer</surname>
<given-names>J.&#x20;H.</given-names>
</name>
<name>
<surname>van der Poll</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>van &#x27;t Veer</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>TAM Receptors, Gas6, and Protein S: Roles in Inflammation and Hemostasis</article-title>. <source>Blood</source> <volume>123</volume> (<issue>16</issue>), <fpage>2460</fpage>&#x2013;<lpage>2469</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2013-09-528752</pub-id> </citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waddell</surname>
<given-names>B. E.</given-names>
</name>
<name>
<surname>Rodriguez-Bigas</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>R. J.</given-names>
</name>
<name>
<surname>Weber</surname>
<given-names>T. K.</given-names>
</name>
<name>
<surname>Petrelli</surname>
<given-names>N. J.</given-names>
</name>
</person-group> (<year>1999</year>). <article-title>Prevention of Chronic Radiation Enteritis</article-title>. <source>J.&#x20;Am. Coll. Surg.</source> <volume>189</volume> (<issue>6</issue>), <fpage>611</fpage>&#x2013;<lpage>624</lpage>. <pub-id pub-id-type="doi">10.1016/s1072-7515(99)00199-4</pub-id> </citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ou</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Albertson</surname>
<given-names>C. M.</given-names>
</name>
<name>
<surname>Fink</surname>
<given-names>L. M.</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>J.&#x20;M.</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>). <article-title>Hirudin Ameliorates Intestinal Radiation Toxicity in the Rat: Support for Thrombin Inhibition as Strategy to Minimize Side-Effects after Radiation Therapy and as Countermeasure against Radiation Exposure</article-title>. <source>J.&#x20;Thromb. Haemost.</source> <volume>2</volume> (<issue>11</issue>), <fpage>2027</fpage>&#x2013;<lpage>2035</lpage>. <pub-id pub-id-type="doi">10.1111/j.1538-7836.2004.00960.x</pub-id> </citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Role of TLR-4 in A-nti-&#x3b2;2-glycoprotein I-induced A-ctivation of P-eritoneal M-acrophages and V-ascular E-ndothelial C-ells in M-ice</article-title>. <source>Mol. Med. Rep.</source> <volume>19</volume> (<issue>5</issue>), <fpage>4353</fpage>&#x2013;<lpage>4363</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2019.10084</pub-id> </citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wyseure</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Rubio</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Denorme</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Martinez de Lizarrondo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Peeters</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gils</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Innovative Thrombolytic Strategy Using a Heterodimer Diabody against TAFI and PAI-1 in Mouse Models of Thrombosis and Stroke</article-title>. <source>Blood</source> <volume>125</volume> (<issue>8</issue>), <fpage>1325</fpage>&#x2013;<lpage>1332</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2014-07-588319</pub-id> </citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>AMPK Activation by Ozone Therapy Inhibits Tissue Factor-Triggered Intestinal Ischemia and Ameliorates Chemotherapeutic Enteritis</article-title>. <source>FASEB J.</source> <volume>34</volume> (<issue>9</issue>), <fpage>13005</fpage>&#x2013;<lpage>13021</lpage>. <pub-id pub-id-type="doi">10.1096/fj.201902717RR</pub-id> </citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Anti-inflammatory and Immunoregulatory Effects of Paeoniflorin and Total Glucosides of Paeony</article-title>. <source>Pharmacol. Ther.</source> <volume>207</volume>, <fpage>107452</fpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2019.107452</pub-id> </citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y. F.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Inhibition of Apoptosis Signal-Regulating Kinase by Paeoniflorin Attenuates Neuroinflammation and Ameliorates Neuropathic Pain</article-title>. <source>J.&#x20;Neuroinflammation</source> <volume>16</volume> (<issue>1</issue>), <fpage>83</fpage>. <pub-id pub-id-type="doi">10.1186/s12974-019-1476-6</pub-id> </citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimmerer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>B&#xf6;cker</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Wenz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Singer</surname>
<given-names>M. V.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Medical Prevention and Treatment of Acute and Chronic Radiation Induced Enteritis-Iis There Any Proven Therapy? a Short Review</article-title>. <source>Z. Gastroenterol.</source> <volume>46</volume> (<issue>5</issue>), <fpage>441</fpage>&#x2013;<lpage>448</lpage>. <pub-id pub-id-type="doi">10.1055/s-2008-1027150</pub-id> </citation>
</ref>
</ref-list>
</back>
</article>